SCHEMBL15720060

SCHEMBL15720060

CCN(CC(=O)O)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
ALDH1A1 P00352 1/20 0.56
KEAP1 Q14145 2/20 0.54
NFE2L2 Q16236 2/20 0.54
POLB P06746 1/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TAS2R14 Q9NYV8 2/20 0.50
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
MMP1 P03956 1/20 0.50
MMP7 P09237 1/20 0.50
MMP8 P22894 1/20 0.50
MMP12 P39900 1/20 0.50
MMP13 P45452 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9972493 0.85 KEAP1 (0.62) KMT2AMEN1ALDH1A1KEAP1NFE2L2
SCHEMBL5285705 0.85 MAPK1 (0.63) KMT2AMEN1ALDH1A1KEAP1NFE2L2
SCHEMBL7461410 0.84 TAS2R14 (0.61) KEAP1NFE2L2TAS2R14MMP1MMP7
SCHEMBL3246445 0.84 ALDH1A1 (0.73) KMT2AMEN1ALDH1A1TSHRMAPK1
SCHEMBL16894098 0.83 MMP1 (0.72) KMT2AMEN1KEAP1NFE2L2POLB
SCHEMBL16894270 0.82 TAS2R14 (0.51) KMT2AMEN1KEAP1NFE2L2MAPK1
SCHEMBL1133869 0.81 MMP8 (0.65) KEAP1NFE2L2LMNAHTTSMN1; SMN2
SCHEMBL16894212 0.81 MAPK1 (0.67) ALDH1A1KEAP1NFE2L2MAPK1LMNA
SCHEMBL22252112 0.80 KEAP1 (0.69) KMT2AKEAP1NFE2L2TAS2R14
SCHEMBL6501947 0.80 KMT2A (0.63) KMT2AMEN1ALDH1A1KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900642-B1 SUBSTITUTED SULFONAMIDE COMPOUNDS HOFFMANN LA ROCHE (CH) 2018-02-28 EP disclosed
US-9580411-B2 Substituted sulfonamide compounds HOFFMANN-LA ROCHE INC. (US) 2017-02-28 US disclosed
US-9359337-B2 Acetamide derivatives HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
US-9359337-B2 Acetamide derivatives HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
US-9359337-B2 Acetamide derivatives HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
EP-2920158-A1 NOVEL ACETAMIDE DERIVATIVES AS TRP CHANNEL ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2015-09-23 EP disclosed
US-20150246906-A1 NOVEL ACETAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-09-03 US disclosed
US-20150246906-A1 NOVEL ACETAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-09-03 US disclosed
US-20150246906-A1 NOVEL ACETAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-09-03 US disclosed
EP-2900642-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS F. Hoffmann-La Roche AG (CH) 2015-08-05 EP disclosed
US-20150197509-A1 SUBSTITUTED SULFONAMIDE SOLUTIONS GENENTECH, INC. (US) 2015-07-16 US disclosed
WO-2014076038-A1 NOVEL ACETAMIDE DERIVATIVES AS TRP CHANNEL ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197509-A1 SUBSTITUTED SULFONAMIDE SOLUTIONS TRPA1, TRPV1, TRPV5 KMT2A 2838/4885MEN1 3909/4885ALDH1A1 949/4885
US-20150246906-A1 NOVEL ACETAMIDE DERIVATIVES ADCY4, ADCY3, ADCY1 KMT2A 1642/4885MEN1 1390/4885ALDH1A1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.